ORIGINAL RESEARCH article
Front. Med.
Sec. Precision Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1624682
A PROPOSED MODEL USING GLYCATION METRICS AND CIRCULATING BIOMARKERS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
Provisionally accepted
- CardiacData Analytics, Winter Park, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cardiovascular aging starts early in life due to the glycation of critical proteins, though its progression remains undetected in the formative years. The glycation reaction affects all tissues by the same non enzymatic irreversible reaction. The variables are the pH, temperature, glucose concentration, and the specific protein. This relationship implies that glycated blood biomarkers could potentially be used as a proxy for assessing in situ myocardial changes.Laboratory tests for troponin I (cTnI), hemoglobin A1c (A1c), fructosamine, and low-density lipoprotein (LDL), were chosen to calculate the proxy for in situ glycation. An algorithm was developed incorporating these variables as individual measurements and as calculated metrics of glycation. This data was obtained from previous large group studies of variables and outcomes.Modeling of glycation was determined for each variable. Using metrics from multiple studies, theoretical rates of glycation of LDL and troponin I were calculated. The glycated changes in LDL and troponin I were used to determine the increases above optimal physiological rates.Laboratory results of LDL, cTnI, A1c and fructosamine could be used sequentially to derive a cost-effective proxy for assessing in situ aging and deterioration of cardiovascular tissue. This model could theoretically predict the rate of cardiovascular aging by integrating four blood biomarkers into a dedicated algorithm guiding proactive diagnostics and treatment.
Keywords: glycation, biomarkers, algorithm, cardiovascular disease, prevention
Received: 07 May 2025; Accepted: 30 Jun 2025.
Copyright: © 2025 Valk and McMorrow. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Timothy Valk, CardiacData Analytics, Winter Park, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.